Clinical trial
A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18…
NCT00485732 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00485732 |
|---|---|
| Title | A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years |
| Official title | A Phase IIIb, Double-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV-16/18 L1 VLP AS04 Vaccine, Administered Intramuscularly in Healthy Female Subjects Aged 15 - 25 Years |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Papillomavirus |
| Intervention type | Biological |
| Interventions | HPV-16/18 VLP/AS04 vaccine (Cervarix TM), Placebo |
| Enrollment | 225 |
| Start date | Jun 11, 2007 |
| Primary completion | Mar 30, 2008 |
| Completion | Mar 30, 2008 |
| First posted | Jun 13, 2007 |
| Last update posted | Jul 20, 2018 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: